CCT241736
Cat. No.:YN440373
产品名称: | CCT241736 |
CAS No.: | 1402709-93-6 |
Chemical Name: | 6-chloro-7-[4-[(4-chlorophenyl)methyl]-1-piperazinyl]-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine |
Synonyms: | CCT241736 |
分子量: | 456.37 |
分子式: | C₂₂H₂₃Cl₂N₇ |
SMILES: | CC1=NN(C)C=C1C2=NC3=C(N4CCN(CC5=CC=C(Cl)C=C5)CC4)C(Cl)=CN=C3N2 |
存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
运输: | Room temperature in continental US; may vary elsewhere. |
产品描述: | CCT241736 是一种有效的,可口服的FLT3和Aurora kinase双重抑制剂,能够有效抑制 Aurora-A (Kd,7.5 nM;IC50,38 nM),Aurora-B (Kd,48 nM),FLT3 (Kd,6.2 nM),以及 FLT3 突变体 FLT3-ITD (Kd,38 nM) 和 FLT3(D835Y) (Kd,14 nM) 的活性。 |
IC50和靶点: | [{name:"Aurora-A:38 nM (IC50)"},{name: "Aurora-A:7.5 nM (Kd)"},{name: "Aurora-B:48 nM (Kd)"},{name: "FLT3:6.2 nM (Kd)"},{name: "FLT3(D835H):11 nM (Kd)"},{name: "FLT3(D835Y):14 nM (Kd)"},{name: "FLT3-ITD:38 nM (Kd)"},{name: "FLT3(K663Q):5.1 nM (Kd)"},{name: "FLT3(N841I):16 nM (Kd)"},{name: "FLT3(R834Q):110 nM (Kd)"}] |
In Vitro: | |
In Vivo: | |
Clinical Trial: | |
Solvent & Solubility: |
Bavetsias, V., Crumpler, S., Sun, C., et al.Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: Identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaJ. Med. Chem.55(20),8721-8734(2012)